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Abstract
Motivation: In silico approaches often fail to utilize bioactivity data available for orthologous tar-
gets due to insufficient evidence highlighting the benefit for such an approach. Deeper investiga-
tion into orthologue chemical space and its influence toward expanding compound and target
coverage is necessary to improve the confidence in this practice.
Results: Here we present analysis of the orthologue chemical space in ChEMBL and PubChem and
its impact on target prediction. We highlight the number of conflicting bioactivities between human
and orthologues is low and annotations are overall compatible. Chemical space analysis shows
orthologues are chemically dissimilar to human with high intra-group similarity, suggesting they
could effectively extend the chemical space modelled. Based on these observations, we show the
benefit of orthologue inclusion in terms of novel target coverage. We also benchmarked predictive
models using a time-series split and also using bioactivities from Chemistry Connect and HTS data
available at AstraZeneca, showing that orthologue bioactivity inclusion statistically improved
performance.
Availability and implementation: Orthologue-based bioactivity prediction and the compound train-
ing set are available at www.github.com/lhm30/PIDGINv2.
Contact: ab454@cam.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
In silico deconvolution is a well-established computational tech-
nique capable of inferring compound activity using similarity rela-
tionships between orphan compounds and identified ligands (Wang
et al., 2013). In this technique, target prediction models can be de-
ployed to produce knowledge-based predictions for new, untested
ligands across a spread of proteins, as shown in Figure 1.
Consequently, it is possible to explore the full bioactivity spectra
across all targets available, to identify patterns present in predicted
space to generate a mode-of-action hypothesis for a previously un-
seen molecular structure (Lavecchia and Cerchia, 2016).
Previous approaches often focus within one species, where bio-
activity information for a single organism is extracted from bioactiv-
ity repositories (Cereto-Massague´ et al., 2015; Ivanov et al., 2016).
In this situation, annotations for orthologous protein relationships,
the closest relative of a given gene in a different species, are disre-
garded. Since orthologues share functional similarity and are likely
to share similar bioactivity profiles, the mapping between species
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offers an attractive approach to integrate bioactivity between related
proteins, to improve the chemical space covered (Dimova et al.,
2015). Mapping activity information to other organisms is also
valuable since small molecules of therapeutic interest are frequently
tested in model organisms before in man.
There are relatively few cheminformatics analyses exploring the
impact of incorporating small molecules binding orthologous pro-
teins in a target prediction context (Koutsoukas et al., 2013). One
study illustrated the mapping of compound interactions across
orthologues improves target prediction accuracy, whilst inclusion of
paralogue data was found to worsen the accuracy in some cases
(Gfeller and Zoete, 2015). These findings outline the potential
advantages of integrating orthologue results across species, but out-
line limitations for such approaches and the need for deeper
investigation.
Various Proteochemometric Modeling (PCM) studies incorpor-
ate orthologues to increase the data available for training. One study
combined bioactivities from Rattus norvegicus with human data
points during PCM training, for the identification of novel adeno-
sine receptor ligands (van Westen et al., 2012). Significant amounts
of rat data were available due to the historical role of this species in
adenosine bioactivity experiments. Protein domain annotations
were extrapolated across species for PCM and in silico target decon-
volution during the retrospective discovery of DHFR inhibitors in
Plasmodium falciparum (Paricharak et al., 2015). Models per-
formed with recall and precision values of 79 and 100%, respect-
ively. HomoloGene (Coordinators, 2013) has also been employed to
improve the coverage of target prediction training data, providing 9
565 534 active and 598 923 798 inactive data points for modelling,
spanning 2 882 targets (Mervin et al., 2016).
Other studies conducted analyses into bioactivity space outside
of a target prediction context, analyzing compound-ligand annota-
tions between related targets in distinct organisms (Klabunde,
2007). A systematic search for bioactive small molecules shared by
orthologous targets identified compound-orthologue pairs, covering
938 orthologues, 358 unique targets and 98 organisms (Dimova
et al., 2015). The authors introduced an orthologue compound-
target classification system comprising “organism cliffs” and “po-
tency-retaining” pairs. An analysis of ChEMBL data demonstrated a
highly significant relationship between bioactivities in human and
rat targets (R¼0.71, p<2e-16), although outliers were identified for
targets such as the Histamine H3 receptor (Kruger and Overington,
2012). Other work mined Homo sapiens bioactivity data together
with structural and historical assay space searches, to propose cross-
species targets alongside respective hit compounds for the treatment
of M.tuberculosis (Martı´nez-Jime´nez et al., 2013). One study com-
prised generation of phylogenetic and bioactivity tree representa-
tions of kinases, highlighting clustering targets in protein structure
space makes incorrect assumptions about interactions in bioactivity
space (Paricharak et al., 2013). In fact, many factors need to be con-
sidered when performing homology-based bioactivity inference
between kinase targets, illustrating the potential pitfalls of extrapo-
lating ligand interactions between species. Recent advances in the
cheminformatics field have also analyzed the influence of other dis-
parate sources of experimental data, showing that even the inclusion
of data from random assays can improve the performance of models
(Ramsundar et al., 2015).
In this study, we verify the advantages and limitations of leverag-
ing the wealth of orthologue bioactivity data for model generation in
a target prediction setting. We address if it is valid to combine ortho-
logue data over the range of targets with available bioactivities in the
first instance, by extracting bioactivity data from ChEMBL (Bento
et al., 2014) and PubChem (Wang et al., 2009) and explore conflict-
ing annotations between human and orthologue bioactivities. We
analyze the concordance of activity values between binding and func-
tional assays in human and orthologue, to test generalizability across
bioactivity data. Chemical space analysis is conducted to explore the
chemical data added to models. For example, if additional bioactivity
data is too similar to existing training data, these compounds are of
lower value since no new information is gained. If training data is too
dissimilar, singleton bioactivity data points could interfere with the
model by diluting the weight of important features.
Finally, we assess the effect of orthologue-based bioactivity infer-
ence on model performance and translatability, using a time-series
split validation of Random Forest, Naı¨ve Bayes and SVM models,
with a range of hyper-parameters in Scikit-learn (Pedregosa et al.,
2011), before and after the inclusion of bioactive orthologue data.
External validation was performed using compounds from
Chemistry Connect (Muresan et al., 2011) and HTS data available
at AstraZeneca. The realized models and training set are available at
www.github.com/lhm30/PIDGINv2.
2 Materials and methods
2.1 Compound bioactivity data and pre-processing
Bioactive molecules were extracted from ChEMBL_21 for
pChEMBL activity values -Log(Ki/Kd/IC50/EC50) greater than or
equal to ‘5’ (10mm) in binding and functional assays for confidence
scores greater than ‘5’ (to ensure protein complexes are included) as
cut-off for active bioactivity. Percentage activation and inhibition
data was also extracted when the ‘Activity Comment’ was declared
‘active’. The dataset contains 766 515 active data points, spanning
1 651 human targets.
Orthologue data from HomoloGene was extracted for non-
human data points spanning 3 231 targets. Bioactivity data for ortho-
logues were integrated with human bioactivity data with the removal
of duplicate SMILES. A total of 114 960 orthologue compounds are
added to 927 different models (56% of the targets modeled).
Targets were filtered for a minimum of 10 training compounds before
mapping, to retain proteins encapsulating sufficient chemical space.
Novel models are available after orthologue inclusion due to surpass-
ing this threshold, which are discussed in Section 3.
Fig. 1. Model evaluation and target deconvolution. Bioactivity data is repre-
sented within a matrix of compounds (rows) and targets (columns). Typically,
target prediction models are trained and evaluated per target or column-wise
(blue), i.e. calculate the performance of a target model given the compounds
retrieved. When the models are deployed for target deconvolution (red), the
models are interpreted per compound (row), i.e. to identify the targets pre-
dicted for a compound. In this work, the evaluation of predictive models is
based on the column-wise assessment of predictions for each new com-
pound (shown)
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PubChem was mined for inactive compounds in the same pro-
cedure to (Mervin et al., 2015) resulting in the extraction of 3 630
485 inactives spanning 1 440 targets. A sphere exclusion algorithm
was applied to sample putative inactive compounds for targets with
insufficient numbers of inactives (1: 100 active versus inactive ratio)
using the protocol in (Mervin et al., 2016). 1 491 615 compounds
were sampled in this way for 711 (43%) targets, producing an in-
active dataset of 5 122 100 molecules.
RDKit (Landrum, 2006) was employed to filter structures with-
out carbon and for atomic numbers between 21 and 32, 36 and 52
and greater than 53, with a molecular weight between 100 and
1 000 Da. Compounds were standardized with ChemAxon
Standardizer (ChemAxon, 2015), with options set to ‘Remove
Fragment’ (keep largest), ‘Neutralize’, ‘RemoveExplicitH’,
‘Clean2d’, ‘Mesomerize’ and ‘Tautomerize’. ChEMBL target-
compound pairs were retained when conflicting inactive bioactiv-
ities arose, since this data is manually curated.
2.2 Target prediction methodology
2 048-bit ECFP_4 binary Morgan fingerprints, radius of 2 atoms,
were generated in RDkit for pre-processed molecules. Scikit-learn
Random Forest (RF) classifiers of ‘5, ‘50’ and ‘500’ trees, with ‘n_
features’ and ‘max_depth’ set to ‘auto’ and ‘class_weight’ set to ‘bal-
anced’, were trained on the fingerprints of active and inactive com-
pounds on a per target basis, whilst supplying the ‘fit’ method the
‘sample_weight’ of the active versus inactive compound ratio.
Bernoulli Naı¨ve Bayes (BNB) models were trained in Scikit-learn
with ‘alpha’ values of ‘1.0’ and ‘0.1’. Lineaer SVM classification
models (SVC) were also trained using Scikit-learn with the kernel set
to ‘linear’ and ‘C’ penalty parameters of ‘1.00e-02’, ‘1.00eþ0’,
‘1.00eþ2’. Platt scaling was performed using the Scikit-learn class
‘CalibratedClassifierCV’ with n_folds set to ‘2’ whilst supplying the
‘sigmoid’ method parameter (Platt, 1999). Platt scaling ensures the
outputs of target models are calibrated to reflect a degree of confi-
dence of the predicted label. This aims to address the applicability
domain, since probabilities from well calibrated classifiers can be in-
terpreted at a confidence level with predictions specified at an ac-
ceptable error rate (Pedregosa et al., 2011).
2.3 Time series split and external performance
evaluation
The Scikit-learn class ‘TimeSeriesSplit’ with ‘n_splits’ set to ‘5’ was used
to perform five-fold time series split cross validation (CV). Chemistry
Connect (Muresan et al., 2011) at AstraZeneca was employed as an ex-
ternal source of bioactivity testing data for activity values (Ki/Kd/IC50/
EC50) less than or equal to 10lM. Duplicate bioactivities to training
data were removed, giving 3061 461 active compounds, covering 572
proteins. 183 099 194 inactive compound-target pairs (distinct from
PubChem) were extracted from 420 AstraZeneca target-based screens,
spanning 88 GPCRs, 77 kinases and 31 proteases. Sphere exclusion
sampled 3 479 469 putative inactive compounds at AstraZeneca, for
targets with insufficient in-house inactivity data. PR-AUC, BEDROC
(‘alpha’¼ ‘20’) (Truchon and Bayly, 2007) and precision, recall and F1-
Scores (at a p(activity) greater than 0.5) were calculated across all folds
per target during internal or external validation.
3 Results
3.1 Exploratory analysis of orthologue bioactivity data
The distribution of orthologue compounds incorporated into models
separated by organism and target class is shown in Supplementary
Table S1, indicating the frequency and distribution of bioactivities
differ between organism and target class. Rattus norvegicus (rat)
and Mus musculus (mouse) contribute the largest number of com-
pounds among the orthologues with 77 156 and 29 119 data points
(67 and 25%), respectively. Although popular for in vivo studies,
Canis lupus familiaris (dog) comprises fewer orthologue target-
compound pairs (433), due to the smaller number of biochemical
assays conducted in vitro for this species. Rat, mouse and Bos taurus
(bovine) contribute 30 814, 3 485 and 1 563 compounds to GPCRs
(across 185 targets), making it the largest target class in terms of
orthologue compounds included. Ion channels are ranked second,
comprising 22 223 bioactive compounds from orthologues, although
they represent a class where the bulk of mapped data points (20 713
compounds for 116 targets) are derived from rat. The Lyase target
class is dominated by bovine data, which contributes 1 179 of the
1 314 bioactivities from orthologues. 1 101 of these are annotated
for ‘Carbonic anhydrase 4’ (CA4), which originate from the popular
purification method of CA4 extraction from bovine lung tissue
(Scozzafava et al., 2012). NHRs, ranked third, are dominated by
‘Nuclear receptor ROR-gamma receptors’ (RORC), due to a
human-orthologue pair between ‘P51449’ and ‘P51450’, with data
from two PubChem qHTS assays (CHEMBL1614441 and
CHEMBL1614087) comprising 11 781 and 7 452 actives, respect-
ively. For contrast, a ROR training set comprising only human data
would only include 418 active compounds.
Although CA4 and RORC dominate their respective target clas-
sifications with 84 and 96% of orthologue compounds, this
should not de-emphasize the impact of minor amounts of bioactiv-
ity data incorporated into under-represented targets. Indeed, one
important aspect to consider when generating in silico target pre-
dictions are biases towards certain protein classifications due to
the irregular distribution of data points in validated bioactivity
space, which are projected forward into predicted bioactivity
space. For example, GPCRs and kinases are examples of well-
studied target classifications where the abundance of data leads to
their significant representation in the targets modeled. One case for
orthologue inclusion is the potential to relax such biases in pre-
dicted bioactivity space by increasing the numbers of targets sur-
passing the minimum threshold for training data. Supplementary
Table S2 shows there are 51 target models which would otherwise
contain too few actives without bioactivity data from orthologues.
The inclusion of these models alleviates the previous biases of tar-
get classes to some extent via improving the representation of mi-
nority classes, with better representation for hydrolases (þ9.17%),
transporters (þ8.05%) and ion channels (þ7.21%). There are
lower (or no) increases for many previously dominating classes,
such as kinases (þ0.00%), proteases (þ2.14%) and GPCRs
(þ2.49%).
Another application of target prediction is the extension of pre-
dicted bioactivity profiles with gene-pathway and gene-disease asso-
ciations, to better rationalize the mode-of-action of compounds
(Mohamad Zobir et al., 2016). On this topic, we analyzed the im-
pact of the new 51 models, in terms of the improved pathway cover-
age from BioSystems (Coordinators, 2013) and diseases from
DisGeNET (Pi~nero et al., 2017). Results show 62 newly accessible
pathways are available when deploying models, with enhanced
coverage for 1 861 pathways. There are 95 novel diseases with im-
proved coverage for 1 388 annotations (Supplementary Table S3).
Many diseases are well-studied, such as ‘Breast Carcinoma’,
‘Schizophrenia’ and ‘Colorectal Cancer’, highlighting the real-world
significance for using orthologue bioactivity space to expand
coverage.
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This section highlights the potential benefits for including bio-
active orthologues in terms of the proportion of data points avail-
able for modelling and the effect this has on the number of targets,
pathways and diseases encapsulated by the realized models.
3.2 Chemical space of the orthologue data
We next analyzed the ECFP_4 Tanimoto coefficient (Tc) nearest
neighbor (NN) similarity between active compounds in orthologue
and human, since the intention of the orthologue mapping is to also
extend the chemical space modeled. Results of the analysis are
shown in Figure 2a, indicating the inclusion of bioactive orthologues
improves the diversity of training data by incorporating dissimilar
areas of chemical space. Almost half (49.6%) of the compounds
have a Tc NN similarity to human compounds less than 0.4. This is
a surprising degree of dissimilarity, considering one study showed
95% of the actives from ChEMBL have a NN Tc similarity greater
than 0.424 for human targets (Mervin et al., 2015). Results indicate
similarity differs by target classification where the disparate chemis-
try for NHRs, a median Tc of 0.22, can be contrasted with the rela-
tively similar bioactive compounds tested for proteases with a Tc of
0.59. The dissimilar chemistry tested between species may arise
from the varying organism specific ADMET properties dependent
on the specific use of compounds at a given target. We also exam-
ined the similarity of compounds within the groups of orthologues
available for each target, to elucidate intra-group chemical diversity.
Figure 2a shows orthologues are more similar to each other than
when compared to their human neighbor counterparts in Figure 2b,
indicating they may be useful for training since they do not comprise
many singleton compounds.
Here we have shown the chemical space contributed by ortho-
logue data is diverse and novel to existing human training data. We
hence expect that integration of both datasets will add value to the
compound training set to be modeled.
3.3 Conflict analysis of orthologue data
One important question when employing orthologue-based bio-
activity inference is the accuracy of assuming shared bioactivity be-
tween orthologues and human targets. To address this question, we
explored the number of cases when a compound is active in
ChEMBL but represented as inactive in PubChem screens in
orthologue and vice-versa. The two sets of results from the compari-
son between conflicting orthologue active and inactive bioactivities
are shown in Supplementary Table S4.
In total, 1 363 of the 124 540 orthologue bioactivities (spanning
206 HomoloGene protein mappings) have conflicting annotation
with the respective compounds inactive in human, indicating con-
flicting bioactivities in 1.2% of cases according to the analysis pre-
sented here. At the target-mapping level, 650 of the 856 human-
orthologue HomoloGene target pairs (75.9%) do not comprise con-
flicting annotations with inactive compounds.
The top 10 conflicting orthologue active and inactive human bio-
activities are shown on the left of Supplementary Table S4, indicat-
ing the top targets comprise GPCRs (4), NHRs (2) and Ion Channels
(2). The proportion of conflicting bioactivities vary widely between
the top-ranking targets, and absolute numbers of disagreements are
sensitive to the size of existing human data. For example, ‘P35372’
to ‘P33535’, ranked first, comprises 85 conflicting bioactivities,
which is proportionately low compared to the 2 291 orthologues
mapped (4% conflict). In comparison, ‘Q00613’ to ‘P38532’,
ranked sixth, comprises 38 conflicting bioactivities and a larger pro-
portion of the 46 orthologue actives mapped (83% conflict).
Multiple sequence alignment was conducted using CLUSTAL
Omega (Version 1.2.4) for the most frequently conflicted targets,
since this is one possible reason for differential activity. The
‘CLUSTAL Sequence Similarity %’ column in Supplementary Table
S4 comprises results from this analysis, indicating high numbers of
conflicting bioactivities are not necessarily correlated with low se-
quence similarity. This observation is likely influenced by the nature
of the alignment, since the active site is unannotated for many top
ranking Uniprot accessions and alignments are forced to reflect
amino acid changes outside ligand binding domains. Our results are
further affected by the requirement for compounds to be tested in
both organisms and for these measurements to show differential ac-
tivity, which is subject to separate testing biases.
The most conflicted target between the human actives and ortho-
logue inactives is the GPCR, ‘Mu-type opioid receptor’ (OPRM1),
comprising HomoloGene mapping between human ‘P35372’ and
rat ‘P33535’. Alignment identifies these two targets as 93.75% simi-
lar, with 7 substitutions within the 400 and 398 amino acid
sequences in the binding domain of both targets. Although these
changes may be responsible for the differential activity and conflict-
ing bioactivity data, this stipulation requires follow-up testing to
corroborate, and the reason for conflicts may also result from
various other factors. One example is annotation error, since
chemogenomic repositories are known to be plagued by both
supplier-specific and repository-specific annotation error rates
(Tiikkainen et al., 2013). Additionally, inactivity mining uses the
‘activity_outcome’ bioactivity flag in PubChem, which has been
shown to comprise conflicting bioactivities with ChEMBL actives
within the same organism (Mervin et al., 2015).
Androgen Receptor (AR) ‘P10275’ to ‘P15207’ is the only
orthologue-target pair within Supplementary Table S4 comprising
X-ray crystal structures for both proteins, affording an opportunity
to superimpose structures between human and orthologue binding
sites to visualize changes responsible for differential activity
(Supplementary Fig. S1). We ascertain the sequences of residues
670–920 within the ligand binding domain are identical in both or-
ganisms, with high structural overlap. Thus, we stipulate AR con-
flicts are due either to flexibility in more distant regions of the
protein, a set of allosteric binding compounds with affinity at the
protein domain not part of the crystal structure (full alignment simi-
larity of 84.44%), or misannotation of compound activity.
Fig. 2. Nearest neighbor analysis. Tanimoto coefficient of ECFP_4 fingerprints
were used to define similarity. (a) Human and orthologue nearest neighbor
similarity indicates the chemical spaces covered by both datasets are dissimi-
lar. This suggests that orthologue data could effectively extend the chemical
space of models. (b) Nearest neighbor analysis indicates orthologues are fre-
quently similar to each other. High intra-group similarity is suited to model-
ling, since this enables models to better identify key features
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In a complementary analysis, we validated the reversed mapping
of orthologue activities, where inactive orthologues from PubChem
are compared to activities from ChEMBL. Overall, 860 of the 3 629
661 inactive compound mappings overlap with actives from
ChEMBL, for 134 of the 420 orthologue target pairs. The top 10
targets from this analysis are shown on the right of Supplementary
Table S4. Nuclear receptor coactivator 3 (NCOA-3) ‘Q9Y6Q9’ is
ranked first, where 138 of the 290 700 mapped inactives have con-
flicting bioactivities with actives (75.4% overlap).
To test how often differential affinity of ligands between ortho-
logues exists in experimentally confirmed results and the validity of
the orthologue-based bioactivity hypothesis in general, we analyzed
the concordance between human and orthologue pChEMBL values
grouped by the ‘standard_units’, ‘standard_type’ and ‘assay_type’
ChEMBL fields. The results, shown in Figure 3, indicate an overall
R2 of 0.455 between bioactivities observed in human and in ortho-
logues. Overall there is a median pChEMBL discordance of 0.51 be-
tween human and orthologue, which is comparable with the median
discordance of 0.48 observed between laboratory measurements for
proteins within the same organism, and 0.42 after discriminating be-
tween assay type (analysis shown in Supplementary Fig. S2).
Overall, 20 608 of the 21 446 compounds (96%) would be con-
sidered active in both human and orthologue using an activity cut-
off of greater than five. A global pChEMBL concordance analysis
separated by orthologue species, shown in Supplementary Figure S3,
also highlighted that highly concordant affinities in species such as
Gallus and Macaca mulatta can be contrasted with more divergent
affinities such as Arabidopsis thaliana, suggesting which organisms
should be prioritized into target prediction models in the future.
Eight of the ten most discordant pChEMBL values, shown in
Supplementary Table S5, exhibit different ChEMBL confidence
scores between the compared experiments, indicating discordant
measurements may be exaggerated due to comparisons between af-
finity values obtained at protein complexes and isolated proteins. A
docking case study analysis (provided in Supplementary Fig. S4) was
conducted for the Nitric oxide synthase orthologue-target pair
ranked third, since ‘P29475’ and ‘P29476’ comprise X-ray crystal
PDB structures and both activities are annotated for the isolated
protein (ChEMBL confidence scores ‘8’ or ‘9’). CHEMBL526688 is
predicted to bind to different amino acid residues in the human and
rat binding sites, thus we stipulate differential activity is due to dif-
ferent observable amino acid changes and binding dynamics within
the orthologous protein.
On this topic, we sought to analyze the influence of the ‘Stats-
prot-change’ field in the HomoloGene repository, measuring the
ratio of amino acid differences (which is only one possible reason
for differences in bioactivity), and the magnitude of disagreement
between human and orthologue pChEMBL values. Supplementary
Figure S5 shows a binned box plot of ‘Stats-prot-change’ between
the human and orthologue targets and the magnitude of difference
between pChEMBL values. We find no trend (R2 of 0.047) between
the magnitude of pChEMBL discordance and the ratio of amino
acid differences, although there is an increase in median pChEMBL
discordance from 0.490 to 0.550, 0.705 and 1.19 within the ‘Stats-
prot-change’ bins of 0.1, 0.2, 0.3 and 0.4, respectively. One import-
ant aspect to consider when interpreting this analysis is that the
‘Stats-prot-change’ field does not specifically consider the active site
of targets, and a signal responsible for divergence or overlap be-
tween orthologues may not be encapsulated in this metric.
This section indicates the frequencies of bioactivity conflicts are
comparatively low between human and orthologue, and that anno-
tations are overall compatible. We suggest conflicts may also origin-
ate from the method of extraction and annotation error, in addition
to differential affinity between proteins. We also indicate the choice
of species and the ‘Stats-prot-change’ metric could help prioritize
higher confidence bioactive orthologues in the future.
3.4 Time series cross validation split of the models
The CV performance of the RF, BNB and SVC algorithms before
and after the inclusion of orthologue training data are shown in scat-
ter plot Figure 4, distribution shown in Supplementary Figure S6
and in tabular form in Supplementary Table S6. Overall, the results
show that the influence of orthologue inclusion differs both between
and within algorithms due to different hyper-parameter settings. For
example, the SVM (C¼1.0Eþ02) showed the largest improvement
upon orthologue inclusion, with 64% of the models showing sta-
ble or improved predictions with median F1-Score increased from
0.616 0.35 to 0.6760.34. Conversely, only 40% of the SVM
(C¼1.0) target prediction models showed improved or stable per-
formance, with a decreased median F1-Score from 0.8460.25 to
0.816 0.25 (which is particularly influenced by decreased median
recall from 0.7860.26 to 0.7260.25), highlighting the extent that
the hyper-parameter selection influences the benefit of orthologue
Fig. 3. Correlation of human and orthologue pChEMBL values. Bioactivity cor-
relation varies between units of measurement and the type of assay. 21 446
compounds are tested in human and orthologue binding (blue) and func-
tional assays (green). The linear regression line is shown with a 95% confi-
dence interval. R2 reflects correlation per Unit
Fig. 4. Five-fold time split cross validation (CV) performance. The influence of
orthologue inclusion varies between algorithms and hyper-parameter
settings
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inclusion and model performance even within the same machine
learning algorithm. In comparison, the RFC showed steady perform-
ance after addition of orthologues across all tested hyper-
parameters, where F1-Score performed within two decimal places
across all 5, 50 and 500 tree hyper-parameter settings. Thus, the
RFC has the highest capacity for maintaining the highest perform-
ance across multiple hyper-parameters despite increasing the num-
ber of data points comprising diverse chemistry from disparate
species.
The distribution of BEDROC performance shows a different be-
havior to the one obtained for F1-Score, since this metric is affected
by orthologue bioactivity to a lesser extent. For example, all eight of
the tested algorithms and hyper-parameter settings demonstrated
similar performance with and without bioactive orthologues within
two percent (three of the eight are identical). This reveals that ortho-
logue inclusion mainly improves models by increasing precision and
recall (and hence F1-Score), but influences the early recognition of
the models to a minor degree. This finding is likely influenced by the
Platt scaling procedure which aims to better calibrate the probability
output by the algorithms, thus models may produce well-adjusted
probabilities with good early recognition (BEDROC) performance
both before and after orthologue inclusion.
Supplementary Figure S7 illustrates internal CV model F1-Score
split by target classification, which enabled us to examine the NHR
target class, since chemical space analysis previously highlighted
that bioactive compounds in orthologue NHRs are both dissimilar
from compounds tested in human and diverse from one another.
Our analysis outlines this protein classification comprises the largest
decrease in F1-Score between all algorithms, with only 25% of mod-
els showing increased or stable performance across all hyper-
parameters (40 out of 160 models tested). Additionally, we have
outlined the number of conflicting bioactivities for the NHR class is
low, with low discordance of pChEMBL values. Based on this
knowledge, we stipulate the observed CV decrease for NHRs is
likely due to the limited number of novel structures with dissimilar
chemistry from actives at each sampling round (rather than the add-
ition of noise from erroneous data points), thus the implemented al-
gorithms are unable to efficiently distinguish orthologue actives
from human inactive training points.
Although some target models are negatively affected by ortho-
logues, this is not automatically a concern for the external applica-
tion of the models since the compounds responsible for performance
decrease will be incorporated into complete training sets, to poten-
tially improve the chemical space of deployed models. We will dis-
sect the performance of these models when extrapolating
predictions to the novel chemistry in the AstraZeneca bioactivity
data, to assess whether orthologues add value to realized models or
form singleton data points confounding the models.
Overall, we show that orthologues incorporate novel chemical
diversity into the training set without a significant negative impact
to performance overall. Results support the view that compounds
active in orthologous targets could enable future predictions to cap-
italize on extended chemical space, to produce superior predictions
with better extrapolation to novel chemistry.
3.5 External validation using AstraZeneca bioactivity
data
We analyzed the performance of the models for AstraZeneca com-
pounds unrepresented in the training data using bioactive com-
pounds from Chemistry Connect and inactive compounds from HTS
screens. The performance from this analysis is shown in the scatter
plot Figure 5, distributions in Supplementary Figure S8 and in tabu-
lar form in Table 1 and Supplementary Table S7. Our findings high-
light decreased performance both before and after orthologue
inclusion compared to CV results (markers towards the bottom left
of the plots), which arises from difficult classification instances
when external testing compounds are distinct from the training set.
Compared to CV, the overall distribution of median F1-Score ex-
ternal validation performance shows stable or improved scores
across all eight of the benchmarked algorithms and hyper-
parameters after incorporation of orthologue bioactivities. In cor-
roboration with CV findings, the scatter plot highlights that the
choice of algorithm and hyper-parameter influences the effect of
orthologue inclusion on model performance to different extents.
The SVM (C¼1.0Eþ02), which was the highest improved algo-
rithm and hyper-parameter for the CV findings, also comprises the
largest F1-Score increase from 0.356 0.28 to 0.436 0.28 after
including orthologue bioactivity (which is due to increased recall
scores from 0.426 0.29 to 0.4760.27). The RFC (Trees¼500)
comprises the second largest improvement in F1-Score performance
from 0.356 0.28 to 0.416 0.28, which is also the highest perform-
ing class during external validation.
The performances of the benchmarked models split by target
classification are visualized in Supplementary Figure S9. In compari-
son to CV, many of the markers lie above the diagonal line, indicat-
ing benefit of orthologue bioactivity space. Ion channels are the
most improved class overall, with large increases across all eight of
the algorithms and hyper-parameters benchmarked, with the largest
Fig. 5. AstraZeneca external validation performance. Decreased performance
towards the bottom left of the plots arises from difficult classification in-
stances in external testing compounds, for compounds that are distinct from
the training set. In accordance with internal CV, the influence of orthologue
inclusion on performance varies between algorithms and hyper-parameter
settings
Table 1. Averaged F1-Score results for AstraZeneca external
validation
Learner Hyper-parameter Without orthologues With orthologues
BNB Alpha ¼ 0.1 0.336 0.29 0.34 6 0.29
Alpha ¼ 1.0 0.356 0.29 0.36 6 0.29
SVM C¼ 1.0E-02 0.446 0.29 0.46 6 0.30
C¼ 1.0E-00 0.386 0.28 0.42 6 0.28
C¼ 1.0Eþ02 0.396 0.27 0.42 6 0.27
RFC Trees ¼ 5 0.336 0.27 0.36 6 0.27
Trees ¼ 50 0.376 0.28 0.40 6 0.28
Trees ¼ 500 0.376 0.28 0.41 6 0.28
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increase obtained by the SVM (C¼1.0Eþ02) for F1-Scores from
0.186 0.19 to 0.356 0.22. We next explored the NHR class, which
was previously outlined as problematic across benchmarked algo-
rithms during CV due to the dissimilar orthologue chemistry that
was not successfully combined into models during time series split
validation. In comparison to CV, the external performance of the
NHR is improved for 53% of the models (more than twice the
number obtained during CV). The largest increase for this class was
observed for the BNB (Alpha¼0.1) models with a median F1-Score
increase of 0.1860.19 to 0.3560.22. This result indicates many of
the previously problematic orthologue compounds have been success-
fully incorporated into the realized models to produce superior per-
formance during AstraZeneca bioactivity external dataset validation.
Although the overall distribution and median scores obtained
from this analysis show general improvement across the breadth of
models, there are many models which are negatively affected by
orthologues across the algorithms and hyper-parameters tested,
which emphasizes the need to individually assess orthologue space
when incorporating this type of bioactivity data points into models.
One reason for decreased performance may be due to the uneven
distribution of orthologues in chemical space. The addition of
singleton compound fingerprints may interfere with the machine
learning algorithm by diluting important features as it attempts to
accommodate islands of activity from orthologue space.
Additionally, larger numbers of orthologues can effectively convert
a human target model into an orthologue model containing fewer
human bioactivities than ones originating from related organisms.
Our results show that combination of orthologue data across all
models should not be performed. Instead, the per-target perform-
ance upon orthologue inclusion for each algorithm and hyper-
parameter should be assessed, to ensure an informed decision is
taken regarding the addition of bioactive compounds from ortho-
logue species into the realized predictors.
4 Discussion
Here we present an in-depth analysis of orthologue bioactivity data
and its relevance and applicability towards expanding compound
and target bioactivity space for predictive studies. We compared the
number of conflicting bioactivities between human actives and
orthologue inactives and vice-versa, indicating annotations are com-
patible in 98.90 and 99.97% of cases. pChEMBL concordance ana-
lysis outlines bioactivity agreement varies between species and
indicates which organisms could be prioritized to supplement future
models. The HomoloGene ‘prot-stat-change’ could be used to re-
move discordant target mappings and could also help direct the pri-
oritization of future bioactivity assays, since higher confidence
annotations with concordance may not require subsequent profiling
in human and vice-versa. Chemical space analysis indicated the
chemistry contributed by orthologue data is both diverse and novel
to existing human training data, suggesting integration of both data-
sets could add value to the training set to be modeled.
We explored the impact of orthologous bioactivity information on
target prediction models using the Random Forest (RF), Bernoulli
Naı¨ve Bayes (BNB) and Support Vector Machine Classifier (SVC) al-
gorithms using five-fold time series cross validation (CV). Overall, re-
sults showed bioactive orthologues incorporate novel and diverse
chemistry into the training set without impacting CV performance,
supporting the view that orthologues enable future predictions to cap-
italize on extended chemical space. External AstraZeneca bioactivity
data showed orthologue inclusion significantly increased performance
across all machine learning algorithms and hyper-parameters, by ena-
bling the realized predictors to access new chemical space. We illus-
trate the influence of orthologues on predictivity varies between
organism and protein classification due to the quantity and diversity
of human and orthologue bioactivities. Ideally, the decision whether
to add orthologues could be considered on a per target basis, con-
sidering the chemical diversity of human and orthologue data and the
biology or disease of interest.
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